Several of the other studies we have supported include:

GREYlong contributed to CD47 Blockade to Enhance Adaptive Anti-tumor Immune Responses (Veterinary Student Katie Anderson, University of Minnesota, Dr. Jaime Modiano, and Dr. Matthew Mescher).  The advantage of an immunological approach, to treat patients that have metastatic cancer, is that it uses the patient's own cells. This makes it easier to reach tumors that are inaccessible for conventional treatments, with fewer side effects. The success of this approach is tied to overcoming barriers that tumors build to evade the immune response. The objective of this study is to develop an approach whereby the patient's immune cells learn to recognize cancer cells at the primary site and eliminate renegade cancer cells before they spread to distant sites and establish metastases.
  
Effect of Tumor Microenvironment on Canine Myeloid Cells (Veterinary Student Scholar Jacob Wasserman, Ohio State University.   Although chemotherapy has been the primary treatment of choice in human and veterinary oncology, chemotherapy is relatively untargeted and has numerous side effects. Stimulating the immune system to target tumor cells offers a potentially more effective and less toxic alternative to chemotherapy alone, and such cancer immunotherapy is being explored in canine and human cancer patients. In cancer, it is thought that myeloid cells, a type of cell derived from marrow, significantly contribute to the immunosuppression seen in cancer patients.  This study was chosen to honor the memory of the Loeser's pet therapy dog, Brooke.
Immunotherapy Treatment